Entheon Biomedical Corp. (ENBI.CN)
CAD 0.1
(-16.67%)
CAD 0.1
(-16.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -313.99 Thousand CAD | 91.16% |
| 2022 | -3.55 Million CAD | 61.88% |
| 2021 | -9.31 Million CAD | -112.97% |
| 2020 | -4.37 Million CAD | -563.98% |
| 2019 | -658.56 Thousand CAD | -287.34% |
| 2018 | -170.01 Thousand CAD | -44.37% |
| 2017 | -117.76 Thousand CAD | -18416.98% |
| 2016 | -636.00 CAD | 92.92% |
| 2015 | -8980.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -102.06 Thousand CAD | -30.98% |
| 2024 Q1 | -77.93 Thousand CAD | -4.11% |
| 2024 Q3 | -67.27 Thousand CAD | 34.09% |
| 2023 Q4 | -74.85 Thousand CAD | 19.07% |
| 2023 FY | -312.81 Thousand CAD | 91.19% |
| 2023 Q1 | -123.21 Thousand CAD | -120.94% |
| 2023 Q3 | -92.48 Thousand CAD | -268.42% |
| 2023 Q2 | -25.1 Thousand CAD | 79.63% |
| 2022 Q4 | 588.41 Thousand CAD | 169.48% |
| 2022 FY | -3.55 Million CAD | 61.88% |
| 2022 Q3 | -846.89 Thousand CAD | 42.17% |
| 2022 Q2 | -1.46 Million CAD | 19.85% |
| 2022 Q1 | -1.82 Million CAD | 23.21% |
| 2021 Q1 | -3.44 Million CAD | -7.41% |
| 2021 Q2 | -1.76 Million CAD | 48.77% |
| 2021 Q3 | -1.71 Million CAD | 2.84% |
| 2021 Q4 | -2.37 Million CAD | -38.62% |
| 2021 FY | -9.31 Million CAD | -112.97% |
| 2020 Q2 | -32.12 Thousand CAD | 10.04% |
| 2020 FY | -4.37 Million CAD | -563.98% |
| 2020 Q4 | -3.21 Million CAD | -2786.87% |
| 2020 Q3 | -111.24 Thousand CAD | -246.28% |
| 2020 Q1 | -35.71 Thousand CAD | 27.71% |
| 2019 Q4 | -49.39 Thousand CAD | -205.33% |
| 2019 Q3 | -16.17 Thousand CAD | 58.0% |
| 2019 Q2 | -38.51 Thousand CAD | 10.0% |
| 2019 FY | -658.56 Thousand CAD | -287.34% |
| 2019 Q1 | -42.79 Thousand CAD | 22.75% |
| 2018 Q1 | -39.98 Thousand CAD | 41.96% |
| 2018 FY | -170.01 Thousand CAD | -44.37% |
| 2018 Q4 | -55.39 Thousand CAD | -61.62% |
| 2018 Q3 | -34.27 Thousand CAD | 8.73% |
| 2018 Q2 | -37.55 Thousand CAD | 6.08% |
| 2017 Q2 | -3614.00 CAD | 0.0% |
| 2017 Q3 | -35.46 Thousand CAD | -881.21% |
| 2017 Q4 | -68.89 Thousand CAD | -94.27% |
| 2017 FY | -117.76 Thousand CAD | -18416.98% |
| 2016 FY | -636.00 CAD | 92.92% |
| 2015 FY | -8980.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 93.743% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 95.933% |
| BetterLife Pharma Inc. | -3.24 Million CAD | 90.31% |
| BioVaxys Technology Corp. | -2.4 Million CAD | 86.931% |
| ChitogenX Inc. | -2.83 Million CAD | 88.905% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | 91.602% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 97.519% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 93.826% |
| Glow Lifetech Corp. | -1.64 Million CAD | 80.886% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | 53.463% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | 58.845% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | 16.853% |
| MYND Life Sciences Inc. | -1.8 Million CAD | 82.631% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | 73.884% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 89.685% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | 67.399% |
| Telescope Innovations Corp. | -5.76 Million CAD | 94.555% |